The Patent Trial and Appeal Board (PTAB) has partly accepted pharmaceutical company Lupin Limited’s petition for an inter partes review (IPR) of claims in a patent covering a compound that helps to treat HIV.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Vertex Pharmaceuticals; Lupin Limited; PTAB; HIV; inter partes review; patents; USPTO; Patent Trial and Appeal Board